YU44898A - Postupak za dobijanje magnezijumove soli supstituisanog heterocikličnog sulfinila - Google Patents

Postupak za dobijanje magnezijumove soli supstituisanog heterocikličnog sulfinila

Info

Publication number
YU44898A
YU44898A YU44898A YU44898A YU44898A YU 44898 A YU44898 A YU 44898A YU 44898 A YU44898 A YU 44898A YU 44898 A YU44898 A YU 44898A YU 44898 A YU44898 A YU 44898A
Authority
YU
Yugoslavia
Prior art keywords
preparation
substituted
magnesium salt
hetericyclic
sulphinyl
Prior art date
Application number
YU44898A
Other languages
English (en)
Inventor
Jan-Ake Hogberg
Panagiotis Ioannidis
Anders Mattson
Original Assignee
Astra Aktiebolag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20402358&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=YU44898(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Aktiebolag filed Critical Astra Aktiebolag
Publication of YU44898A publication Critical patent/YU44898A/sh
Publication of RS49718B publication Critical patent/RS49718B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Novi postupak dobijanja magnezijumove soli jedinjenja supstituisanog heterocikličnog sulfinila, koje sadrži imidazol, formule (I). Postupak se ostvaruje mešanjem supstituisanog heterocikla formule (I) sa slabom bazom i izvorom magnezijuma. Baza i izvor magnezijuma se biraju tako da se ono što se dobije kao ostatak lako može odvojiti za vreme odigravanja reakcije. Ovaj pronalazak se takodje odnosi na upotrebu dobijenih jedinjenja u medicini.
YUP-448/98A 1996-04-26 1998-10-14 Postupak dobijanja magnezijumove soli supstituisanog heterocikličnog sulfinila RS49718B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9601598A SE508669C2 (sv) 1996-04-26 1996-04-26 Nytt förfarande

Publications (2)

Publication Number Publication Date
YU44898A true YU44898A (sh) 1999-07-28
RS49718B RS49718B (sr) 2007-12-31

Family

ID=20402358

Country Status (40)

Country Link
US (1) US6124464A (sh)
EP (1) EP0897386B1 (sh)
JP (1) JP4233115B2 (sh)
KR (1) KR100468331B1 (sh)
CN (1) CN1100776C (sh)
AR (1) AR006640A1 (sh)
AT (1) ATE222904T1 (sh)
BR (1) BR9708829A (sh)
CA (1) CA2251636C (sh)
CZ (1) CZ295067B6 (sh)
DE (1) DE69714987T2 (sh)
DK (1) DK0897386T3 (sh)
DZ (1) DZ2209A1 (sh)
EE (1) EE03485B1 (sh)
EG (1) EG23874A (sh)
ES (1) ES2180981T3 (sh)
HK (1) HK1016978A1 (sh)
HR (1) HRP970210B1 (sh)
HU (1) HUP9901798A3 (sh)
ID (1) ID16685A (sh)
IL (1) IL126716A (sh)
IS (1) IS1984B (sh)
MA (1) MA24143A1 (sh)
MY (1) MY119011A (sh)
NO (1) NO318850B1 (sh)
NZ (1) NZ332154A (sh)
PL (1) PL188824B1 (sh)
PT (1) PT897386E (sh)
RS (1) RS49718B (sh)
RU (1) RU2163238C2 (sh)
SA (1) SA97170759B1 (sh)
SE (1) SE508669C2 (sh)
SI (1) SI0897386T1 (sh)
SK (1) SK282752B6 (sh)
TN (1) TNSN97068A1 (sh)
TR (1) TR199802156T2 (sh)
TW (1) TW420676B (sh)
UA (1) UA51699C2 (sh)
WO (1) WO1997041114A1 (sh)
ZA (1) ZA973153B (sh)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875872B1 (en) * 1993-05-28 2005-04-05 Astrazeneca Compounds
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
DE19843413C1 (de) 1998-08-18 2000-03-30 Byk Gulden Lomberg Chem Fab Neue Salzform von Pantoprazol
KR100619200B1 (ko) * 1998-11-18 2006-09-05 아스트라제네카 아베 개선된 화학적 제조 방법 및 제약 제형
CA2290893C (en) * 1999-11-16 2007-05-01 Bernard Charles Sherman Magnesium omeprazole
WO2002012225A1 (fr) * 2000-08-04 2002-02-14 Takeda Chemical Industries, Ltd. Sels de composé à base de benzimidazole et leurs applications
MXPA04007169A (es) * 2002-01-25 2004-10-29 Santarus Inc Suministro transmucosal de inhibidores de bomba de protones.
ES2286408T3 (es) * 2002-03-05 2007-12-01 Astrazeneca Ab Sales de alquilamonio de omeprazol e esomeprazol.
TW200410955A (en) * 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
DE10234617B4 (de) * 2002-07-29 2013-04-04 Nycomed Gmbh Neues Salz von (S)-Pantoprazol
EP1556043A1 (en) * 2002-10-22 2005-07-27 Ranbaxy Laboratories, Ltd. Amorphous form of esomeprazole salts
US20040242642A1 (en) * 2002-11-18 2004-12-02 Dr. Reddy's Laboratories Limited Crystalline esomeprazole compounds and process for the preparation thereof
WO2004056804A2 (en) * 2002-12-19 2004-07-08 Teva Pharmaceutical Industries Ltd. Solid states of pantoprazole sodium, processes for preparing them and processes for preparing known pantoprazole sodium hydrates
BRPI0407906A (pt) * 2003-02-28 2006-02-14 Ranbaxy Lab Ltd polimorfos de s-omeprazol
CL2004000983A1 (es) 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
PE20050150A1 (es) 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
WO2005012289A1 (en) * 2003-07-17 2005-02-10 Altana Pharma Ag Novel salt of (r) - pantoprazole
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
SE0302382D0 (sv) * 2003-09-04 2003-09-04 Astrazeneca Ab New salts II
SE0302381D0 (sv) 2003-09-04 2003-09-04 Astrazeneca Ab New salts I
ITMI20031813A1 (it) * 2003-09-23 2005-03-24 Dinamite Dipharma S P A In Forma A Bbreviata Diph Procedimento per la preparazione di pantoprazolo e suoi sali.
WO2005082888A1 (en) * 2004-03-01 2005-09-09 Milen Merkez Ilac Endustrisi A.S. Process for the preparation of magnesium salt of omeprazole
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
ES2246149B1 (es) * 2004-07-02 2007-06-01 Esteve Quimica, S.A. Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion.
US20060141054A1 (en) 2004-10-25 2006-06-29 Thomas Piccariello Metal coordinated compositions
US7799937B2 (en) 2004-10-25 2010-09-21 Synthonics, Inc. Metal coordinated compositions
US8779175B2 (en) 2004-10-25 2014-07-15 Synthonics, Inc. Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients
EP1801110A1 (en) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Esomeprazole arginine salt
US7553857B2 (en) 2005-12-23 2009-06-30 Lek Pharmaceuticals D.D. S-omeprazole magnesium
EP1954691A2 (en) 2006-06-12 2008-08-13 Teva Pharmaceutical Industries Ltd Amorphous and crystalline forms of pantoprazole magnesium salt
EP1947099A1 (en) 2007-01-18 2008-07-23 LEK Pharmaceuticals D.D. Process for solvent removal from omeprazole salts
EP2125783A2 (en) 2007-02-21 2009-12-02 Cipla Limited Process for the preparation of esomeprazole magnesium dihydrate
US8106210B2 (en) * 2007-10-08 2012-01-31 Hetero Drugs Limited Polymorphs of esomeprazole salts
EP2147918A1 (en) 2008-07-21 2010-01-27 LEK Pharmaceuticals D.D. Process for the preparation of S-omeprazole magnesium in a stable form
WO2010097583A1 (en) 2009-02-24 2010-09-02 Cipla Limited Esomeprazole potassium polymorph and its preparation
US20110207779A1 (en) * 2010-02-25 2011-08-25 Glenmark Generics Ltd Process for the preparation of esomeprazole magnesium
EP2426111A1 (en) 2010-08-09 2012-03-07 Laboratorios Del. Dr. Esteve, S.A. 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms
CN103467453A (zh) * 2013-09-13 2013-12-25 上海海虹实业(集团)巢湖今辰药业有限公司 一种奥美拉唑镁原料药制备方法
CN106397399A (zh) * 2015-07-29 2017-02-15 陕西合成药业股份有限公司 一种泮托拉唑镁的精制方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
GB8307865D0 (en) * 1983-03-22 1983-04-27 Fujisawa Pharmaceutical Co Benzimidazole derivatives
FI861772A (fi) * 1985-05-07 1986-11-08 Chemie Linz Ag Nya tieno(2,3-d)imidazolderivat och foerfarande for deras framstaellning.
FI864138A (fi) * 1985-10-16 1987-04-17 Fisons Plc Heterocykliska blandningar.
NZ244301A (en) * 1991-09-20 1994-08-26 Merck & Co Inc Preparation of 2-pyridylmethylsulphinylbenzimidazole and pyridoimidazole derivatives from the corresponding sulphenyl compounds
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
UA41946C2 (uk) * 1994-07-08 2001-10-15 Астра Актієболаг Оральна фармацевтична складова одинична дозована форма у вигляді таблетки, спосіб її одержання, упаковка у вигляді блістера та спосіб інгібування секреції шлункової кислоти і/або лікування шлунково-кишкових запальних захворювань

Also Published As

Publication number Publication date
NO318850B1 (no) 2005-05-18
HRP970210B1 (en) 2002-06-30
TW420676B (en) 2001-02-01
NO984903D0 (no) 1998-10-21
KR20000065018A (ko) 2000-11-06
SK282752B6 (sk) 2002-12-03
TNSN97068A1 (fr) 1999-12-31
EE03485B1 (et) 2001-08-15
RU2163238C2 (ru) 2001-02-20
DK0897386T3 (da) 2002-10-28
AU2719397A (en) 1997-11-19
EP0897386A1 (en) 1999-02-24
HUP9901798A2 (hu) 2000-04-28
IS4872A (is) 1998-10-19
NO984903L (no) 1998-10-21
MY119011A (en) 2005-03-31
MA24143A1 (fr) 1997-12-31
DZ2209A1 (fr) 2002-12-03
CN1216989A (zh) 1999-05-19
AU711345B2 (en) 1999-10-14
UA51699C2 (uk) 2002-12-16
WO1997041114A1 (en) 1997-11-06
SE9601598L (sv) 1997-10-27
TR199802156T2 (xx) 1999-02-22
KR100468331B1 (ko) 2005-03-16
SE508669C2 (sv) 1998-10-26
DE69714987T2 (de) 2003-04-30
NZ332154A (en) 2002-03-01
CA2251636A1 (en) 1997-11-06
ID16685A (id) 1997-10-30
ATE222904T1 (de) 2002-09-15
SI0897386T1 (en) 2002-12-31
CN1100776C (zh) 2003-02-05
IL126716A0 (en) 1999-08-17
IS1984B (is) 2005-02-15
ES2180981T3 (es) 2003-02-16
CZ339898A3 (cs) 1999-03-17
EG23874A (en) 2007-11-27
PT897386E (pt) 2002-12-31
SK140798A3 (en) 1999-04-13
US6124464A (en) 2000-09-26
HUP9901798A3 (en) 2003-02-28
JP4233115B2 (ja) 2009-03-04
AR006640A1 (es) 1999-09-08
JP2000509067A (ja) 2000-07-18
EE9800363A (et) 1999-04-15
EP0897386B1 (en) 2002-08-28
PL188824B1 (pl) 2005-04-29
SE9601598D0 (sv) 1996-04-26
CA2251636C (en) 2001-04-10
SA97170759B1 (ar) 2006-09-25
HK1016978A1 (en) 1999-11-12
BR9708829A (pt) 1999-08-03
HRP970210A2 (en) 1998-04-30
IL126716A (en) 2003-10-31
RS49718B (sr) 2007-12-31
CZ295067B6 (cs) 2005-05-18
PL329683A1 (en) 1999-04-12
ZA973153B (en) 1997-10-27
DE69714987D1 (de) 2002-10-02

Similar Documents

Publication Publication Date Title
YU44898A (sh) Postupak za dobijanje magnezijumove soli supstituisanog heterocikličnog sulfinila
YU38799A (sh) Disupstituisani biciklični heterocikli,njihovo dobijanje i njihova primena kao lekova
MXPA02004415A (es) Pirazolonas sustituidas con heterociclicas.
DE69723869D1 (de) Heterozyklische verbindungen, verfahren zu ihrer herstellung, pharmazeutische zusammensetzungen die diese enthalten und ihre anwendung in der behandlung von diabetis und verwandten krankheiten
TNSN00202A1 (fr) Derives de n-[(purine - 2- yl) methyl]-sulfonamide nouveaux, procede pour leur preparation et compositions les contenant
BR0111230A (pt) Composto, e, uso e processo para a preparação do mesmo
DK0956282T3 (da) Sulfinsyrederivater, fremgangsmåde til deres fremstilling og anvendelse
BR0013041A (pt) Composto heterociclico e composição farmacêutica para tratar e prevenir doenças mediadas por cgmp-pde, seu uso e método
DE60220255T2 (de) N-phenylarylsulfonamidverbindung, arzneimittel, das diese verbindung als wirkstoff enthält, zwischenprodukt für die verbindung und verfahren zu dessen herstellung
TNSN01131A1 (fr) Derives de phenoxybenzylamine nouveaux, procede pour leur preparation et compositions les contenant.
EA200601065A1 (ru) Производные имидазола, способы их получения и применения
YU75101A (sh) Supstituisani biciklični heterocikli, postupak njihove izrade i njihova upotreba kao antigojaznih i hipoholesterolemijskih agenasa
BR0211826A (pt) Imidazopiridinas tricìclicas
TNSN07006A1 (en) Novel heterocyclic compounds
EA199900754A1 (ru) Способ получения замещенного тиазолидиндиона
NO20053928L (no) Fremgangsmate for a fremstille ondansetron og intermediater derav.
AR036735A1 (es) Derivados de 5-metoxi-8-aril-[1,2,4]triazolo[1,5-a]piridina
GB0215392D0 (en) Chemical compounds
ID30435A (id) Proses-proses untuk menyiapkan perantara-perantara pestisidal
CA2421826A1 (en) Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
MEP16708A (en) Acylaminothiazole derivatives, preparation method thereof and use of same as beta-amyloid peptide production inhibitors
EA200000924A3 (ru) СПОСОБ ПОЛУЧЕНИЯ ПИРАЗОЛО[4,3-d]ПИРИМИДИН-7-ОН-3-ПИРИДИЛСУЛЬФОНИЛЬНЫХ СОЕДИНЕНИЙ И ИХ ПРОМЕЖУТОЧНЫХ СОЕДИНЕНИЙ
NO20055991L (no) Fremgangsmate for syntetisering av heterocykliske forbindelser
NO306714B1 (no) Krystallinsk, polymorf form av (S,S,S)-N-(1-[2-karboksy-3-(N2-mesyllysylamino)propyl]-1-cyklopentylkarbonyl)-tyrosin
GB0102407D0 (en) Process